US: 1.646.568.9797 (24x5)
UK: 44.330.808.0580 (24x5)
Worldwide: 91.703.051.960 (24x7)
Anti-obesity drugs are the drugs that help in reducing or controlling body mass, either by decreasing the craving or increasing the consumption of calories. Appetite control is achieved through the use of agonists for appetite suppressing pathways. Geographically, North America captures the largest market share on account of increasing obese population. As per the historical trends, more than one-third of the U.S. population is obese. However, Asia Pacific is anticipated to grow at the fastest rate due to increasing demand for the drugs and awareness about the risk associated with obesity. According to WHO, 13.0% of the population were obese in 2014. In developing countries the rate of childhood obesity is increasing and has been 30.0% higher than that of developed countries. The global Anti-Obesity Therapeutics market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. This report focuses on Anti-Obesity Therapeutics volume and value at global level, regional level and company level. From a global perspective, this report represents overall Anti-Obesity Therapeutics market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan. At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.
The following manufacturers are covered:
Segment by Regions
- Bristol-Myers Squibb
- Eisai Company
- FlaxoSithKline plc.
- Novo Nordisk
- BoehringerIngelheim GmbH
- Takeda Pharmaceutical
- Rhythm Pharmaceuticals
- Shionogi USA
- Norgine Pharmaceuticals Ltd.
- North America
Segment by Type
- Centrally Acting Anti-obesity Drugs
- Peripherally Acting Anti-obesity Drugs
Segment by Application
- Hospital Use
- Clinic Use
In Aug 2020,Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Hanmi Pharmaceutical today announced that the companies have entered into an exclusive licensing agreement for the development, manufacture and commercialization of efinopegdutide (formerly HM12525A),Hanmi’s investigational once-weekly glucagon-like peptide-1 (GLP-1)/glucagon receptor dual agonist, for the treatment of nonalcoholic steatohepatitis (NASH). Under the agreement, Merck will be granted an exclusive license to develop, manufacture and commercializeefinopegdutidein the United States and globally. Hanmi will receive an upfront payment of $10 million and is eligible to receive milestone payments up to $860 million associated with the development, regulatory approval and commercialization of efinopegdutide,as well as double-digit royalties on sales of approved product. Hanmi retains an option to commercialize efinopegdutide in Korea. Efinopegdutide is a GLP-1/glucagon receptor dual agonist, which activates both the GLP-1 and glucagon receptors. The safety and efficacy of efinopegdutide has previously been evaluated in multiple Phase 1 and Phase 2 clinical trials, including for the treatment of severely obese individuals with and without type 2 diabetes mellitus.
Research Methodology: Global Metabolic Disorder Therapeutics Market
- Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please Request a Sample Report.
- Demand Side Primary Contributors: OEMs, Industrial Professionals, Researches, Suppliers and Distributors, Group Purchasing Organizations, Associations, Insurers, Universities, Technological Writers, Scientists, Promoters, Investors among others.
- Supply Side Primary Contributors: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, Regulatory Affairs Managers among others.
Table of Contents Executive Summary 1 Anti-Obesity Therapeutics Market Overview 1.1 Product Overview and Scope of Anti-Obesity Therapeutics 1.2 Anti-Obesity Therapeutics Segment by Type 1.2.1 Global Anti-Obesity Therapeutics Production Growth Rate Comparison by Type (2014-2025) 1.2.2 Centrally Acting Anti-obesity Drugs 1.2.3 Peripherally Acting Anti-obesity Drugs 1.3 Anti-Obesity Therapeutics Segment by Application 1.3.1 Anti-Obesity Therapeutics Consumption Comparison by Application (2014-2025) 1.3.2 Hospital Use 1.3.3 Clinic Use 1.3.4 Household 1.3.5 Other 1.4 Global Anti-Obesity Therapeutics Market by Region 1.4.1 Global Anti-Obesity Therapeutics Market Size Region 1.4.2 North America Status and Prospect (2014-2025) 1.4.3 Europe Status and Prospect (2014-2025) 1.4.4 China Status and Prospect (2014-2025) 1.4.5 Japan Status and Prospect (2014-2025) 1.5 Global Anti-Obesity Therapeutics Market Size 1.5.1 Global Anti-Obesity Therapeutics Revenue (2014-2025) 1.5.2 Global Anti-Obesity Therapeutics Production (2014-2025) 2 Global Anti-Obesity Therapeutics Market Competition by Manufacturers 2.1 Global Anti-Obesity Therapeutics Production Market Share by Manufacturers (2014-2019) 2.2 Global Anti-Obesity Therapeutics Revenue Share by Manufacturers (2014-2019) 2.3 Global Anti-Obesity Therapeutics Average Price by Manufacturers (2014-2019) 2.4 Manufacturers Anti-Obesity Therapeutics Production Sites, Area Served, Product Types 2.5 Anti-Obesity Therapeutics Market Competitive Situation and Trends 2.5.1 Anti-Obesity Therapeutics Market Concentration Rate 2.5.2 Anti-Obesity Therapeutics Market Share of Top 3 and Top 5 Manufacturers 2.5.3 Mergers & Acquisitions, Expansion 3 Global Anti-Obesity Therapeutics Production Market Share by Regions 3.1 Global Anti-Obesity Therapeutics Production Market Share by Regions 3.2 Global Anti-Obesity Therapeutics Revenue Market Share by Regions (2014-2019) 3.3 Global Anti-Obesity Therapeutics Production, Revenue, Price and Gross Margin (2014-2019) 3.4 North America Anti-Obesity Therapeutics Production 3.4.1 North America Anti-Obesity Therapeutics Production Growth Rate (2014-2019) 3.4.2 North America Anti-Obesity Therapeutics Production, Revenue, Price and Gross Margin (2014-2019) ... | read more...